MAIA Biotechnology (MAIA) Assets Average (2022 - 2026)

MAIA Biotechnology (MAIA) has reported Assets Average for 5 consecutive years, with $22.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 104.48% year-over-year to $22.5 million; the TTM figure through Mar 2026 stood at $22.5 million (up 104.48% YoY), while the FY2025 annual figure was $9.9 million, up 12.06% from the prior year.
• Assets Average rose to $22.5 million in Q1 2026 per MAIA's latest filing, from $10.7 million in the prior quarter.
• Across five years, Assets Average topped out at $22.5 million in Q1 2026 and bottomed at $7.3 million in Q4 2023.
• Historically, Assets Average has averaged $11.2 million across 5 years, with a median of $10.6 million in 2024.
• Annual changes were most pronounced in 2023 — Assets Average plunged 45.65% — and 2026, when it soared 104.48%.
• MAIA Biotechnology's Assets Average stood at $13.4 million in 2022, then plunged by 45.65% to $7.3 million in 2023, then surged by 33.16% to $9.7 million in 2024, then climbed by 10.77% to $10.7 million in 2025, then surged by 109.56% to $22.5 million in 2026.
• Business Quant data shows MAIA's Assets Average at $22.5 million in Q1 2026, $10.7 million in Q4 2025, and $11.4 million in Q3 2025.